Search results for "discontinuation"
showing 10 items of 193 documents
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register
2014
Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…
Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative…
2012
1077 Background: 1st-line BEV combined with weekly PAC significantly improves progression-free survival (PFS) and response rate (RR) vs PAC alone in HER2-negative mBC, as shown in E2100. We analyzed data from a German routine oncology practice study of 1st-line BEV–PAC according to prognostic factors. Methods: Pts who had received no prior chemotherapy for mBC received BEV–PAC according to the European label. Efficacy and safety were documented for up to 1 y (or until progression, death, or BEV discontinuation if earlier) with additional long-term follow-up. Efficacy was analyzed in clinically important subgroups. Results: Efficacy data were available for 818 pts. The median duration of fo…
Verlängerte Sekundärprophylaxe nach venöser Thromboembolie
2018
Was ist neu? Aktuelle Studien Kurz nach Absetzen der oralen Antikoagulation kommt es zu einem etwa 2- bis 3-fachen Anstieg von VTE-Rezidiven. Das Rezidivrisiko ist besonders hoch nach einer VTE, die ohne identifizierbaren Auslöser aufgetreten war oder wenn nur weiche, unsichere auslösende Risikofaktoren vorlagen, sowie bei fortbestehenden Risikofaktoren, wie z. B. einer Krebserkrankung. Konsensusdokument über auslösende Risikofaktoren für venöse Thromboembolie In einem aktuellen Konsensusdokument wurden die zugrundeliegenden Risikofaktoren definiert und in 3 Gruppen klassifiziert. Direkte orale Antikoagulanzien Eine reduzierte Dosis von DOAK ermöglicht eine wirksame verlängerte Sekundärprop…
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
2021
AbstractSevere asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible for both biologics, but not optimally controlled by omalizumab. We retrospectively enrolled uncontrolled severe asthmatic patients who switched from OMA to MEP during the last two years. Information included blood eosinophil count, asthma control test (ACT), spirometry, serum IgE, fractional exhaled nitric oxide (FeNO), OCS intake, drugs, exacerbations/hospitalizations, visits and diagno…
Reason for treatment abandonment from the perspective of the patient with an eating disorder
2016
Los tratamientos psicológicos y farmacológicos para los trastornos de la conducta alimentaria comportan costes personales y sanitarios. En este trabajo estudiamos los diferentes motivos que pueden estar asociados al abandono en ambos tipos de tratamientos en pacientes diagnosticados con un trastorno de la conducta alimentaria, así como el tipo de abandono: abandono tras evaluar, abandono precoz y tardío. Por otro lado, analizamos si existe alguna relación entre el diagnóstico y el tipo de abandono. Se examinaron diversas características (edad, sexo, diagnóstico, motivos y tipos de abandono, y satisfacción respecto a la unidad de trastornos de la conducta alimentaria) en 212 pacientes atendi…
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study
2021
This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan-Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9-1…
Umorzenie postępowania karnego na podstawie art. 59a k.k. – wybrane zagadnienia
2016
Discontinuation of proceedings under Article 59a of the Criminal Code is a new institution in Polish criminal law. This article discusses selected issues relating to the premises for the application of Article 59a of the Criminal Code in practice. In view of the use by the legislator in Article 59a of the Criminal Code of concepts with vague meanings, their possible interpretations were proposed. It has been suggested that a rephrasing of the provision in ąuestion should be considered, in order to ensure the possibility of applying the said institution to a wider range of misdemeanours, as compensatory discontinuation is intended by the legislator to fulfil the redress function of proceedin…
Type 1 diabetes in an adolescent with social problems and mental disorders – case report
2021
W cukrzycy typu 1 przerwanie leczenia (insulinoterapii) prowadzi do cukrzycowej kwasicy ketonowej (DKA), będącej stanem bezpośredniego zagrożenia życia. Celem przedstawionego opisu przypadku jest zwrócenie uwagi na sytuację pacjentów z cukrzycą typu 1 i istotnymi problemami socjalnymi/psychicznymi, którzy ze względu na brak odpowiednich uregulowań prawnych „wypadają z systemu”, który mógłby zapewnić im odpowiednią opiekę warunkującą prawidłowe leczenie. Zaburzenia psychiczne i/lub problemy socjalne utrudniają lub uniemożliwiają prowadzenie samokontroli i leczenia. Pacjenci tacy stanowią istotne wyzwanie dla zespołu diabetologicznego i wymagają zindywidualizowanego postępowania ze strony sys…
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refract…
2018
ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-escalation study with six different dosing schedules. The primary endpoint was frequency and severity of adverse events (AEs). Secondary endpoints included pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Sixty-five patients received solitomab at doses between 1 and 96 µg/day for ≥28 days. Fifteen patients had dose-limiting toxicities (DLTs): e…
Seizure following the Use of the COX-2 Inhibitor Etoricoxib
2017
We describe a case of epileptic seizures occurring after the use of a COX-2 inhibitor. A 61-year-old man was admitted to our department because of a generalized tonic-clonic seizure. EEG showed generalized slowdown of the activity. Neuroimaging and blood samples studies did not evidence alterations, but a careful pharmacological history revealed that the patient had taken the COX-2 inhibitor etoricoxib to treat lumbago few days before the onset of clinical symptoms. No seizures were reported after etoricoxib discontinuation and an EEG resulted to be normal two months after this. Conclusion. Knowing the pharmacological history of a patient is important for understanding the clinical presenta…